Combined Spironolactone and Irbesartan Inhibits Myocardial Fibrosis in Renovascular Hypertensive Rats
Lists
Only you see this
Abstract
Background Studies have shown aldosterone could induce cardiac fibrosis and upregulate protein expression of connective tissue growth factor (CTGF) only in serum and glucocorticoid-regulated protein kinase (SGK)+/+ but not in SGK-/-mice,indicating that SGK1 plays a decisive role in aldosterone-induced cardiac fibrosis. It remains elusive whether spironolactone and irbesartan can inhibit the expression of SGK1. Objective To investigate the effects of spironolactone and irbesartan on the myocardial fibrosis and its mechanisms. Methods Thirty-two hypertensive Sprague-Dawley(SD) rats induced by two kidney,one -clip (2K1C) method were randomized to receive following approaches: placebo group (n=8),spironolactone group[Spi,20 mg/(kg·d),n=8],irbesartan group [Irb,50 mg/(kg·d),n=8] and combination group [Com,Spi 20 mg/(kg·d)+Irb 50 mg/(kg·d),n=8]. Age matched SD underwent sham operation (n=8) as control. Eight weeks after operation,the hydroxyproline content of left ventricle myocardium,perivascular collagen area/luminal area ratio(PVCA/LA),collagen volume fraction(CVF) were measured. Plasma and myocardial aldosterone were detected by radioimmunoassay,and expressions of SGK1,CTGF were measured by Western blot. Results The arterial pressure,the hydroxyproline content of myocardium,PVCA/LA,CVF and the expressions of SGK1,CTGF were increased in rats of RHR. After 8 weeks' treatment,spironolactone didn't decrease SBP,but irbesartan and combination treatment markedly decreased SBP(P0.01). Besides the hydroxyproline content of myocardium,decreases in PVCA/LA,CVF and the expressions of SGK1,CTGF were shown by all treatments. However,the effect by combinedtreatment was much better than that of monotherapy (P0.01 or P0.05). Combination treatment furthermore decreased the levels of aldosterone in plasma and myocardium. Conclusion The combined treatment of spironolactone and irbesartan was better than the monotherapy in attenuating myocardial fibrosis,which was associated with decreases in SGK1 and CTGF expression.
BibTeX
@inproceedings{hu2009combined,
author = {Xue Lei Hu},
title = {{Combined Spironolactone and Irbesartan Inhibits Myocardial Fibrosis in Renovascular Hypertensive Rats}},
booktitle = {Chinese},
year = {2009},
}Loading related content...